Exogenous melatonin ameliorates steroid-induced osteonecrosis of the femoral head by modulating ferroptosis through GDF15-mediated signaling.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Melatonin (MT) | decrease | bone loss | SONFH rats | - | alleviated | #1 |
Melatonin (MT) | increase | BMSC activity | SONFH rats | - | maintaining | #2 |
Melatonin (MT) | decrease | ferroptosis | SONFH rats | - | suppression of | #3 |
melatonin MT2 receptor antagonist | no change | MT | - | - | block the therapeutic effects of | #4 |
- | decrease | growth differentiation factor 15 (GDF15) | SONFH process | - | downregulated | #5 |
MT treatment | increase | GDF15 | bone marrow mesenchymal stem cells | - | increased the expression of | #6 |
shGDF15 | no change | melatonin | - | - | confirmed that GDF15 plays a key role in the therapeutic effects of | #7 |
MT | decrease | SONFH | - | - | attenuated | #8 |
MT | decrease | ferroptosis | - | - | inhibiting | #9 |
supplementation with exogenous MT | no change | SONFH | - | - | might be a promising method for the treatment of | #10 |
BACKGROUND: Ferroptosis is an iron-related form of programmed cell death. Accumulating evidence has identified the pathogenic role of ferroptosis in multiple orthopedic disorders. However, the relationship between ferroptosis and SONFH is still unclear. In addition, despite being a common disease in orthopedics, there is still no effective treatment for SONFH. Therefore, clarifying the pathogenic mechanism of SONFH and investigating pharmacologic inhibitors from approved clinical drugs for SONFH is an effective strategy for clinical translation. Melatonin (MT), an endocrine hormone that has become a popular dietary supplement because of its excellent antioxidation, was supplemented from an external source to treat glucocorticoid-induced damage in this study. METHODS: Methylprednisolone, a commonly used glucocorticoid in the clinic, was selected to simulate glucocorticoid-induced injury in the current study. Ferroptosis was observed through the detection of ferroptosis-associated genes, lipid peroxidation and mitochondrial function. Bioinformatics analysis was performed to explore the mechanism of SONFH. In addition, a melatonin receptor antagonist and shGDF15 were applied to block the therapeutic effect of MT to further confirm the mechanism. Finally, cell experiments and the SONFH rat model were used to detect the therapeutic effects of MT. RESULTS: MT alleviated bone loss in SONFH rats by maintaining BMSC activity through suppression of ferroptosis. The results are further verified by the melatonin MT2 receptor antagonist that can block the therapeutic effects of MT. In addition, bioinformatic analysis and subsequent experiments confirmed that growth differentiation factor 15 (GDF15), a stress response cytokine, was downregulated in the process of SONFH. On the contrary, MT treatment increased the expression of GDF15 in bone marrow mesenchymal stem cells. Lastly, rescue experiments performed with shGDF15 confirmed that GDF15 plays a key role in the therapeutic effects of melatonin. CONCLUSIONS: We proposed that MT attenuated SONFH by inhibiting ferroptosis through the regulation of GDF15, and supplementation with exogenous MT might be a promising method for the treatment of SONFH.